Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer
TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ — Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (“Foresee”), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical…
Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
— Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol — STAINES-UPON-THAMES, United Kingdom, Feb. 21, 2019 /PRNewswire/ —…
Shanghai Concord Medical Cancer Center’s Basic Medical Services have been Fully Covered by Medical Insurance
BEIJING, Feb. 20, 2019 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solution provider and operator of a network…
ROKIT Healthcare Announces a Novel Application of Dermal Regeneration Platform Using Proprietary Three-Dimensional Bioprinting Strategy
Applications of the treatment will expand to different indications in need to regenerative therapeutic strategies, including scar removal, burns, and pressure/diabetic foot ulcers SEOUL, South Korea, Feb. 20, 2019 /PRNewswire/…
Avidity Science™ Celebrates 50 Years Of Excellence
WATERFORD, Wisconsin, Feb. 20, 2019 /PRNewswire/ — Avidity Science launches its golden anniversary today with a year-long celebration of achievements and milestones from the past 50 years. From humble beginnings…
Future of Clinical Laboratories: How to Adapt Your Strategy to the Declining Reimbursements and Be Successful
Transformational Health experts and industry thought leaders lead a webinar on how deploying data-driven approach is necessary to track analytics and test utilization parameters SANTA CLARA, Calif., Feb. 19, 2019…
Merck Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
– Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research – Helps modify difficult-to-access regions of the genome, increasing genome coverage DARMSTADT, Germany, Feb. 19,…
AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002
COPENHAGEN, Denmark and AMSTERDAM, Feb. 19, 2019 /PRNewswire/ — AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and Calypso Biotech B.V. (Calypso), a biotechnology company…
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2019 Financial Results
-Earnings Call Scheduled for 8:00 a.m. ET on February 26, 2019 HONG KONG, Feb. 19, 2019 /PRNewswire/ — Global Cord Blood Corporation (NYSE: CO) (the “Company”), China’s leading provider of…
Berry Genomics and Prenetics Announce Key Management Hires for Consumer Genetics Testing Platform
New Company to be called “Circle DNA” and operational by Q2 2019 Ex-Senior Executive from Google China joins as CEO Global genetics testing market expected to be worth USD 50-billion…
